The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.
wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Albert J. Czaja

Division of Gastroenterology and Hepatology

Mayo Clinic College of Medicine

200 First Street S.W.

Rochester

USA

[email]@mayo.edu

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, 200 First Street S.W., Rochester, USA. 1999 - 2012
  • Mayo Clinic and Mayo Clinic College of Medicine, Division of Gastroenterology and Hepatology, Department of Medicine, 200 First Street SW, USA. 2008

References

  1. Advances in the current treatment of autoimmune hepatitis. Czaja, A.J. Dig. Dis. Sci. (2012) [Pubmed]
  2. Nonstandard Drugs and Feasible New Interventions for Autoimmune Hepatitis: Part II. Czaja, A.J. Inflamm. Allergy. Drug. Targets (2012) [Pubmed]
  3. Nonstandard drugs and feasible new interventions for autoimmune hepatitis: part I. Czaja, A.J. Inflamm. Allergy. Drug. Targets (2012) [Pubmed]
  4. Diagnosis, pathogenesis, and treatment of autoimmune hepatitis after liver transplantation. Czaja, A.J. Dig. Dis. Sci. (2012) [Pubmed]
  5. Drug choices in autoimmune hepatitis: Part B - nonsteroids. Czaja, A.J. Expert. Rev. Gastroenterol. Hepatol (2012) [Pubmed]
  6. Drug choices in autoimmune hepatitis: Part A - steroids. Czaja, A.J. Expert. Rev. Gastroenterol. Hepatol (2012) [Pubmed]
  7. Autoantibody-negative autoimmune hepatitis. Czaja, A.J. Dig. Dis. Sci. (2012) [Pubmed]
  8. Promising pharmacological, molecular and cellular treatments of autoimmune hepatitis. Czaja, A.J. Curr. Pharm. Des. (2011) [Pubmed]
  9. Drug-induced autoimmune-like hepatitis. Czaja, A.J. Dig. Dis. Sci. (2011) [Pubmed]
  10. Performance parameters of the conventional serological markers for autoimmune hepatitis. Czaja, A.J. Dig. Dis. Sci. (2011) [Pubmed]
  11. Difficult treatment decisions in autoimmune hepatitis. Czaja, A.J. World J. Gastroenterol. (2010) [Pubmed]
  12. Advances in the diagnosis, pathogenesis, and management of autoimmune hepatitis. Czaja, A.J., Manns, M.P. Gastroenterology (2010) [Pubmed]
  13. Autoantibodies as prognostic markers in autoimmune liver disease. Czaja, A.J. Dig. Dis. Sci. (2010) [Pubmed]
  14. Emerging opportunities for site-specific molecular and cellular interventions in autoimmune hepatitis. Czaja, A.J. Dig. Dis. Sci. (2010) [Pubmed]
  15. Animal models of autoimmune hepatitis. Czaja, A.J. Expert. Rev. Gastroenterol. Hepatol (2010) [Pubmed]
  16. Autoimmune liver disease. Czaja, A.J. Curr. Opin. Gastroenterol. (2009) [Pubmed]
  17. Current and future treatments of autoimmune hepatitis. Czaja, A.J. Expert. Rev. Gastroenterol. Hepatol (2009) [Pubmed]
  18. Features and consequences of untreated type 1 autoimmune hepatitis. Czaja, A.J. Liver Int. (2009) [Pubmed]
  19. Rapidity of treatment response and outcome in type 1 autoimmune hepatitis. Czaja, A.J. J. Hepatol. (2009) [Pubmed]
  20. Special clinical challenges in autoimmune hepatitis: the elderly, males, pregnancy, mild disease, fulminant onset, and nonwhite patients. Czaja, A.J. Semin. Liver Dis. (2009) [Pubmed]
  21. Progress in the diagnosis and treatment of autoimmune hepatitis. Czaja, A.J. Minerva Med. (2008) [Pubmed]
  22. Clinical features, differential diagnosis and treatment of autoimmune hepatitis in the elderly. Czaja, A.J. Drugs. Aging (2008) [Pubmed]
  23. HLA DRB1*13 as a risk factor for type 1 autoimmune hepatitis in North American patients. Czaja, A.J., Carpenter, H.A., Moore, S.B. Dig. Dis. Sci. (2008) [Pubmed]
  24. Genetic factors affecting the occurrence, clinical phenotype, and outcome of autoimmune hepatitis. Czaja, A.J. Clin. Gastroenterol. Hepatol. (2008) [Pubmed]
  25. Autoimmune liver disease. Czaja, A.J. Curr. Opin. Gastroenterol. (2008) [Pubmed]
  26. Safety issues in the management of autoimmune hepatitis. Czaja, A.J. Expert. Opin. Drug. Saf (2008) [Pubmed]
  27. Arthur Joseph McCullough, Jr., 58th President, AASLD. Czaja, A.J., Tavill, A.S. Hepatology (2008) [Pubmed]
  28. Performance parameters of the diagnostic scoring systems for autoimmune hepatitis. Czaja, A.J. Hepatology (2008) [Pubmed]
  29. Autoimmune liver disease. Czaja, A.J. Curr. Opin. Gastroenterol. (2007) [Pubmed]
  30. Evolving concepts in the diagnosis, pathogenesis and treatment of autoimmune hepatitis. Czaja, A.J. Minerva. Gastroenterol. Dietol (2007) [Pubmed]
  31. Autoimmune hepatitis. Part B: diagnosis. Czaja, A.J. Expert. Rev. Gastroenterol. Hepatol (2007) [Pubmed]
  32. Autoimmune hepatitis. Part A: pathogenesis. Czaja, A.J. Expert. Rev. Gastroenterol. Hepatol (2007) [Pubmed]
  33. Autoimmune liver disease and rheumatic manifestations. Czaja, A.J. Curr. Opin. Rheumatol (2007) [Pubmed]
  34. Optimizing diagnosis from the medical liver biopsy. Czaja, A.J., Carpenter, H.A. Clin. Gastroenterol. Hepatol. (2007) [Pubmed]
  35. Distinctive clinical phenotype and treatment outcome of type 1 autoimmune hepatitis in the elderly. Czaja, A.J., Carpenter, H.A. Hepatology (2006) [Pubmed]
  36. Autoimmune liver disease. Czaja, A.J. Curr. Opin. Gastroenterol. (2006) [Pubmed]
  37. Clinical and HLA phenotypes of type 1 autoimmune hepatitis in North American patients outside DR3 and DR4. Czaja, A.J., Carpenter, H.A., Moore, S.B. Liver Int. (2006) [Pubmed]
  38. Thiopurine methyltransferase deficiency and azathioprine intolerance in autoimmune hepatitis. Czaja, A.J., Carpenter, H.A. Dig. Dis. Sci. (2006) [Pubmed]
  39. Treatment challenges and investigational opportunities in autoimmune hepatitis. Czaja, A.J., Bianchi, F.B., Carpenter, H.A., Krawitt, E.L., Lohse, A.W., Manns, M.P., McFarlane, I.G., Mieli-Vergani, G., Toda, G., Vergani, D., Vierling, J., Zeniya, M. Hepatology (2005) [Pubmed]
  40. Current concepts in autoimmune hepatitis. Czaja, A.J. Ann. Hepatol (2005) [Pubmed]
  41. Autoimmune liver disease. Czaja, A.J. Curr. Opin. Gastroenterol. (2005) [Pubmed]
  42. Empiric therapy of autoimmune hepatitis with mycophenolate mofetil: comparison with conventional treatment for refractory disease. Czaja, A.J., Carpenter, H.A. J. Clin. Gastroenterol. (2005) [Pubmed]
  43. Diverse manifestations and evolving treatments of autoimmune hepatitis. Czaja, A.J. Minerva. Gastroenterol. Dietol (2005) [Pubmed]
  44. Decreased fibrosis during corticosteroid therapy of autoimmune hepatitis. Czaja, A.J., Carpenter, H.A. J. Hepatol. (2004) [Pubmed]
  45. Progressive fibrosis during corticosteroid therapy of autoimmune hepatitis. Czaja, A.J., Carpenter, H.A. Hepatology (2004) [Pubmed]
  46. Frequency and significance of antibodies to Saccharomyces cerevisiae in autoimmune hepatitis. Czaja, A.J., Shums, Z., Donaldson, P.T., Norman, G.L. Dig. Dis. Sci. (2004) [Pubmed]
  47. Diagnostic and therapeutic implications of bile duct injury in autoimmune hepatitis. Czaja, A.J., Muratori, P., Muratori, L., Carpenter, H.A., Bianchi, F.B. Liver Int. (2004) [Pubmed]
  48. Autoimmune liver disease. Czaja, A.J. Curr. Opin. Gastroenterol. (2004) [Pubmed]
  49. Histological features associated with relapse after corticosteroid withdrawal in type 1 autoimmune hepatitis. Czaja, A.J., Carpenter, H.A. Liver Int. (2003) [Pubmed]
  50. Autoantibodies in the diagnosis and management of liver disease. Czaja, A.J., Norman, G.L. J. Clin. Gastroenterol. (2003) [Pubmed]
  51. Autoimmune liver disease. Czaja, A.J. Curr. Opin. Gastroenterol. (2003) [Pubmed]
  52. Sustained remission after corticosteroid therapy for type 1 autoimmune hepatitis: a retrospective analysis. Czaja, A.J., Menon, K.V., Carpenter, H.A. Hepatology (2002) [Pubmed]
  53. Autoimmune hepatitis after liver transplantation and other lessons of self-intolerance. Czaja, A.J. Liver Transpl. (2002) [Pubmed]
  54. Diagnosis and treatment of autoimmune hepatitis. Czaja, A.J., Freese, D.K. Hepatology (2002) [Pubmed]
  55. Clinical distinctions and pathogenic implications of type 1 autoimmune hepatitis in Brazil and the United States. Czaja, A.J., Souto, E.O., Bittencourt, P.L., Cancado, E.L., Porta, G., Goldberg, A.C., Donaldson, P.T. J. Hepatol. (2002) [Pubmed]
  56. Treatment strategies in autoimmune hepatitis. Czaja, A.J. Clin. Liver. Dis (2002) [Pubmed]
  57. Autoimmune hepatitis. Czaja, A.J. Clin. Liver. Dis (2002) [Pubmed]
  58. Treatment of autoimmune hepatitis. Czaja, A.J. Semin. Liver Dis. (2002) [Pubmed]
  59. Frequency and significance of antibodies to soluble liver antigen/liver pancreas in variant autoimmune hepatitis. Czaja, A.J., Shums, Z., Norman, G.L. Autoimmunity (2002) [Pubmed]
  60. Emerging treatments for autoimmune hepatitis. Czaja, A.J. Curr. Drug. Targets. Inflamm. Allergy (2002) [Pubmed]
  61. Autoimmune liver disease. Czaja, A.J. Curr. Opin. Gastroenterol. (2002) [Pubmed]
  62. Autoantibodies in liver disease. Czaja, A.J., Homburger, H.A. Gastroenterology (2001) [Pubmed]
  63. Autoimmune hepatitis with incidental histologic features of bile duct injury. Czaja, A.J., Carpenter, H.A. Hepatology (2001) [Pubmed]
  64. Autoimmune liver disease. Czaja, A.J. Curr. Opin. Gastroenterol. (2001) [Pubmed]
  65. Autoimmune hepatitis: the investigational and clinical challenges. Czaja, A.J., Manns, M.P., McFarlane, I.G., Hoofnagle, J.H. Hepatology (2000) [Pubmed]
  66. Genetic susceptibilities for immune expression and liver cell injury in autoimmune hepatitis. Czaja, A.J., Donaldson, P.T. Immunol. Rev. (2000) [Pubmed]
  67. Autoimmune cholangitis within the spectrum of autoimmune liver disease. Czaja, A.J., Carpenter, H.A., Santrach, P.J., Moore, S.B. Hepatology (2000) [Pubmed]
  68. Failure of budesonide in a pilot study of treatment-dependent autoimmune hepatitis. Czaja, A.J., Lindor, K.D. Gastroenterology (2000) [Pubmed]
  69. Cytokine polymorphisms associated with clinical features and treatment outcome in type 1 autoimmune hepatitis. Czaja, A.J., Cookson, S., Constantini, P.K., Clare, M., Underhill, J.A., Donaldson, P.T. Gastroenterology (1999) [Pubmed]
  70. Ursodeoxycholic acid as adjunctive therapy for problematic type 1 autoimmune hepatitis: a randomized placebo-controlled treatment trial. Czaja, A.J., Carpenter, H.A., Lindor, K.D. Hepatology (1999) [Pubmed]
 
WikiGenes - Universities